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Abstract
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide leading to 31% of all global 
deaths. Early prediction and prevention could greatly reduce the enormous socio-economic burden posed by CVDs. Plasma 
lipids have been at the center stage of the prediction and prevention strategies for CVDs that have mostly relied on traditional 
lipids (total cholesterol, total triglycerides, HDL-C and LDL-C). The tremendous advancement in the field of lipidomics in 
last two decades has facilitated the research efforts to unravel the metabolic dysregulation in CVDs and their genetic deter-
minants, enabling the understanding of pathophysiological mechanisms and identification of predictive biomarkers, beyond 
traditional lipids. This review presents an overview of the application of lipidomics in epidemiological and genetic studies 
and their contributions to the current understanding of the field. We review findings of these studies and discuss examples 
that demonstrates the potential of lipidomics in revealing new biology not captured by traditional lipids and lipoprotein 
measurements. The promising findings from these studies have raised new opportunities in the fields of personalized and 
predictive medicine for CVDs. The review further discusses prospects of integrating emerging genomics tools with the high-
dimensional lipidome to move forward from the statistical associations towards biological understanding, therapeutic target 
development and risk prediction. We believe that integrating genomics with lipidome holds a great potential but further 
advancements in statistical and computational tools are needed to handle the high-dimensional and correlated lipidome.
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Introduction
Cardiovascular diseases (CVDs) are a group of complex 
disorders affecting heart function, vascular structure and 
circulatory system. Genetic and epidemiological studies 
have greatly improved our understanding of pathophysiology 
underlying the complex CVDs and have identified several 
risk factors for CVDs. Amongst the well-recognized pre-
disposing factors (Fig. 1), lipid metabolism plays a central 
role in the development of CVDs [1, 2]. Since the landmark 
publications from the Framingham study [3], plasma lipids 
have been recognized as important predictors of future CVD 
events, with lipid lowering as a well-established interven-
tion to reduce CVD risk [4]. To assess CVD risk, plasma 
lipids are routinely monitored by profiling total cholesterol, 
triglycerides, high-density lipoprotein cholesterol (HDL-C) 
and low-density lipoprotein cholesterol (LDL-C) (referred as 
“traditional lipids”). Despite these advances, CVDs remain 
the leading cause of mortality and morbidity worldwide [5], 
as the current preventive strategies are ineffective in a large 
proportion of the population [6].
Human plasma is estimated to consist of thousands of 
functionally and chemically diverse molecular lipid species 
[7–9]. Because of the technological challenges to detect 
diverse yet structurally similar lipids and their isomers, 
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efforts to understand the role of lipids in CVD pathophysi-
ology had largely focused on traditional lipids, and to some 
extent on free fatty acids and lipoproteins, until last decade. 
Nevertheless, there have been tremendous advancements 
in the field of lipidomics that has facilitated the efforts to 
unravel the metabolic dysregulation in complex lipid-related 
disorders, particularly CVDs and to identify predictive 
biomarkers beyond traditional lipids [10, 11]. The prom-
ising findings from epidemiological studies have also led 
to a growing interest in understanding the genetic regula-
tion of lipid metabolism at molecular lipid species level. 
Consequently, genome-wide association studies (GWAS) of 
lipidome profiles, have not only identified new genetic loci/
genes influencing distinct molecular species but have also 
provided novel mechanistic insights to the known genetic 
loci associated with traditional lipids [12, 13].
This review presents an overview of the application of 
lipidomics in epidemiological and genetic studies of CVDs 
and their contributions to the current understanding of the 
field, along with a brief overview of lipidome diversity and 
commonly used analytical approaches. The review further 
discusses some new opportunities provided by integrat-
ing emerging genomics tools with the high-dimensional 
lipidome to move forward from the statistical associations 
towards therapeutic target development and personalized 
medicine with better prediction and prevention.
Human plasma lipidome
Lipidome, the total lipid content in a cell or tissue, is esti-
mated to contain  ~ 200,000 different molecular species 
with different abundance [9]. This extreme diversity arises 
from the extraordinary number of possible combinations of 
various head groups with numerous fatty acids of varying 
length and degree of unsaturation that are esterified to the 
head groups. The LIPID MAPS Initiative and the Interna-
tional Committee for the Classification and Nomenclature 
of Lipids (ICCNL) have provided a standard nomencla-
ture that classifies lipids into eight categories—fatty acyls, 
glycerolipids, glycerophospholipids, sphingolipids, sterols, 
prenols, saccharolipids and polyketides [14–16]. Lipids 
in each lipid category are further divided into classes and 
subclasses based on the head group and type of linkages 
[17, https ://www.lipid maps.org/].
The technological advances have tremendously helped 
in revealing the complexity of lipidome. The LIPID MAPS 
consortium revealed over 500 molecular lipid species 
from 6 major lipid categories, with over 200 and 160 dis-
tinct species of sphingolipids and glycerophospholipids 
respectively [18]. A lipidome analysis of human platelets 
detected over 5,600 unique lipids, with ~ 50% unidentified 
molecular species [19]. The major lipid categories that are 
Fig. 1  Cardiovascular diseases 
and their risk factors. CVDs 
encompass a broad range of dis-
orders affecting the heart, brain 
and blood vessels. The different 
manifestations of CVDs include 
myocardial infarction, stroke 
and peripheral artery disease. 
A number of modifiable and 
non-modifiable risk factors have 
been identified that predispose 
individuals to CVDs. Relation-
ships between lifestyle factors 
and lipids are well known and 
have been the target for preven-
tion strategies
2567Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases 
1 3
commonly identified in plasma lipidomics are discussed 
briefly here (Fig. 2), but are reviewed in detail in [7, 15, 
18, 20, 21].
Fatty acyls
Fatty acyls represent the most fundamental category of the 
lipids including fatty acids. Mostly present in esterified form 
with glycerol, cholesterol or other lipid components, fatty 
acids are carboxylic acids, often with long unbranched ali-
phatic chains of diverse length. Fatty acids are categorized 
as saturated (no carbon–carbon double bonds in aliphatic 
chain) and unsaturated with one (monounsaturated fatty 
acid-MUFA) or more double bonds (polyunsaturated fatty 
acid-PUFA). Human body can synthesize many of these fatty 
acids, except some essential fatty acids including linoleic 
Fig. 2  Human plasma lipidome. Six major lipid categories, of eight 
described by the LIPID MAPS classification system, are illustrated 
with their classes/subclasses and structure of representative of each 
lipid category. As shown, esterification of fatty acids with different 
backbone generates complex lipids including glycerolipids, glycer-
ophospholipids and sphingolipds. Lipids in each lipid category are 
further divided into classes and subclasses based on the head group 
and type of linkages between the backbone and acyl chains [https ://
www.lipid maps.org/]
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acid (omega-6 PUFA) and alpha-linolenic acid (omega-3 
PUFA). These two PUFAs are precursors for other omega-6 
and omega-3 PUFAs that play crucial roles in regulating 
lipid metabolism and atherosclerosis [reviewed in 22, 23].
Glycerolipids
Esterification of one, two or three fatty acyls to glycerol 
lead to the formation of glycerolipids and are accordingly 
classified as monoacylglycerol (MG), diacylglycerol (DG) 
and triacylglycerol (TG). Glycerolipids are a large group 
of lipids accounting for a high proportion of total lipids in 
plasma. TG is the most abundant lipid class and comprises 
the bulk of storage fat in tissues. MGs and DGs represent 
intermediates in the biosynthesis and hydrolysis of TGs and 
function as second messengers in signal transduction pro-
cesses [24, 25].
Glycerophospholipids
Also known as phospholipids, glycerophospholipids are 
diacylglycerides with a phosphatidyl ester attached to the 
terminal carbon. The terminal ester groups are mainly etha-
nolamine, choline, serine or inositol (Fig. 2). In addition, a 
number of fatty acids with varying length and unsaturation 
could attach to the remaining hydroxyl groups of glycerol 
via either acyl-, alkyl-, or alkenyl-bonds [18]. Hydrolysis of 
one of the fatty acids of the phospholipids by phospholipase 
A2 (PLA2) generates respective lysophospholipids, adding 
to the diversity of the lipid pool. Glycerophospholipids are 
the major structural component of cell membranes and are 
involved in various biological processes including inflam-
mation [21].
Sphingolipids
Sphingolipids are wide-range of complex lipids defined 
by 18-carbon sphingoid base, usually sphingosine (SPH). 
Condensation of SPH and free fatty acid generates the sim-
plest sphingolipids, ceramides which function as precursor 
for complex sphingolipids produced by the modification of 
hydroxyl group with phosphocholine (in sphingomyelins) or 
carbohydrates (in gangliosides) (Figs. 2, 3) [21, 26]. Sphin-
golipids constitute several hundreds of different species 
Fig. 3  Role of sphingolipid 
associated loci in major sphin-
golipid metabolic pathways. 
Most of the sphingolipid associ-
ated loci contain genes that code 
for enzymes (highlighted in red 
font) involved in sphingolipid 
metabolic pathways. SGPP1 
codes for a S1P phosphatase 
that catalyzes the degradation of 
sphingosine-1-P to sphingosine 
to facilitate ceramides synthesis 
catalyzed by ceramide synthases 
(CERS1-6) including CERS4 
and CERS6. SPTLC3 gene 
encodes a subunit of the serine 
palmitoyltransferase complex 
which catalyzes the rate-lim-
iting step of de novo pathway 
in sphingolipid biosynthesis. 
FADS1-2-3 locus encodes 
enzymes that regulate the 
desaturation of fatty acids and 
have important role in genera-
tion of unsaturated ceramides. 
GLTPD2 codes for glycolipid 
transfer protein domain-contain-
ing protein 2 and has putative 
role in transfer of ceramide-
1-phosphate
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originating from the combinations of different sphingoid 
bases, various fatty acids that can attach to the bases and 
numerous carbohydrates in gangliosides. Ceramide regulates 
numerous cellular processes such as proliferation, differen-
tiation, and cell signalling [27].
Sterol lipids
Sterols typically have a sterol nucleus composed of four 
tightly fused carbon rings and a hydroxyl group attached to 
the first ring [28]. Cholesterol, the well-known and widely 
measured lipid, is the simplest and most abundant sterol in 
plasma, accounting for more than 99% of all plasma sterols. 
Cholesterol exits in both free and esterified forms as choles-
terol esters, mainly in association with lipoproteins.
Prenols
Prenols are synthesized from five-carbon isoprene units that 
can be combined in wide variety of polymeric units and 
configuration to make diverse products [21]. Prenols include 
vitamins A, E and carotenoids and are essential for immune 
system or regulatory functions in the brain [21]. Prenols are 
understudied in the current lipidomic technologies.
Analytical methods in lipidomics
Of the hundreds of thousands of distinct lipid structures 
that are estimated to occur in nature, only a small fraction 
of lipids has been identified so far, highlighting the lack 
of knowledge and importance of development of high-
throughput screening methods for lipid identification and 
profiling. There are two main approaches in lipidomics: (a) 
targeted approach that focuses on detection of known lipids 
using pre-existing knowledge and (b) non-targeted approach 
that screens all the lipid species without preselection. Non-
targeted approach provides large coverage but is limited 
by the complexity of data processing and identification of 
lipids from large number of signals. Given the structural 
diversity of lipid species, no single analytical method could 
capture the entire lipidome, hence many different methods 
have been employed [reviewed in 29–35]. Here we briefly 
discuss two methods—Nuclear Magnetic Resonance (NMR) 
spectroscopy and Mass spectrometry (MS), that have been 
used commonly in the epidemiological and genetic studies 
of lipidome in the context of CVDs.
Lipidome analysis using NMR spectrometry is based 
on the measurement of magnetic spin of nuclei (1H, 13C, 
15N and 31P) contained in the lipids. NMR can efficiently 
and accurately quantify density, size and particle number of 
different lipoprotein subclasses along with their total lipid 
content (e.g., total TGs, total phospholipids, total cholesteryl 
esters, total sphingolipids in HDLs, LDLs, and very-low-
density lipoprotein (VLDL)) [35]. Identification of indi-
vidual lipid species within lipoprotein subclasses is difficult 
using NMR. As lipid composition of various lipoprotein 
subclasses varies considerably, NMR has been applied to 
measure lipid content in lipoproteins to examine their rela-
tionship with CVDs [36, 37] and to determine their genetic 
determinants [38–42].
MS, on the other hand, provides higher resolution of 
molecular composition of lipidome [reviewed in 31–34]. 
MS is either coupled with prior chromatographic separa-
tion such as gas chromatography (GC–MS) and liquid 
chromatography (LC–MS), or involve direct infusion of 
lipid extract (shotgun lipidomics). LC–MS which provides 
excellent separation efficiency, high sensitivity and strong 
specificity, is one of the most important and widely used 
methods for lipidomics research (Table 1, Supplementary 
Table 2). Liquid chromatography separates lipids based 
on their physiochemical properties, i.e., polar head group, 
carbon chain length, number of double bonds. After chro-
matographic separation, the isolated lipids are ionized that 
are detected using a mass analyser [31]. GC–MS provides 
limited coverage of the lipidome and hence, is restricted 
to studies focused on specific lipid classes and fatty acids 
quantifications [43–45]. In recent times, shotgun lipidomics 
has gain popularity due to its relative simplicity of operation 
and short run times to quantify hundreds of lipids [32–34] 
and has been applied in several large-scale studies [12, 46, 
47]. Shotgun lipidomics technology directly infuses lipids 
extract into an electrospray ionization mass spectrometer 
for the detection of lipids, without chromatographic separa-
tion. Shotgun lipidomics has lower sensitivity than LC–MS 
and hence many of the low abundant lipid species are not 
captured in shotgun lipidomic approaches.
Lipidomics in CVD risk prediction
With the advances in high-throughput lipidomics technolo-
gies, several studies were undertaken to perform in-depth 
examination of role of distinct lipid species in CVDs. The 
studies and their major findings are described in Supple-
mentary Table 1. Taken together, findings from these studies 
suggest: (1) ceramides as prognostic markers for CVDs, (2) 
opposite effects of saturated or MUFA containing lipids and 
PUFA containing lipids on the risk of future CVD events or 
death, and (3) distinct role of TG species based on carbon 
content (Table 1).
Ceramides as prognostic markers for CVDs
Though first regarded as inert components of cell mem-
brane, sphingolipids have emerged as important bioactive 
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molecules owing to their wide-range of biological functions. 
Of particular note is the link between ceramides and CVDs 
mediated through atherosclerotic processes by promoting 
LDL infiltration into blood vessel wall, aggregation of LDL 
in arterial plaque and accumulation of cholesterol in mac-
rophages [48, 49]. Findings from in vitro and in vivo animal 
studies have also supported their role in cardiometabolic dis-
orders including atherosclerosis, and heart failure [27]. In 
this regard, lipidomics of human plasma in large cohorts not 
only reinforced the role of ceramides in CVD manifestations, 
but has also pointed to the distinct ceramide species which 
are independent predictors of future CVD events or death.
Relationship between distinct ceramide species, 
particularly Cer(d18:1/16:0), Cer(d18:1/18:0) and 
Cer(d18:1/24:1), and CVD mortality was first suggested by 
the LURIC study [50], which was supported by report from 
Table 1  Major findings of lipidomics-based epidemiological studies of CVDs
CAD coronary artery disease, CE cholesteryl ester, Cer ceramide, CHD coronary heart disease, DG diacylglyceride, LPC lysophosphatidylcho-
line, LPE lysophosphatidylethanolamine, LC–MS liquid chromatography–mass spectrometry, MACE major adverse cardiovascular event, MS 
mass spectrometry, NMR nuclear magnetic resonance, PC phosphatidylcholine, PC O phosphatidylcholine–ether, PE phosphatidylethanolamine, 
PE O phosphatidylethanolamine–ether, SM sphingomyelin, TG triacyglycerol
Study Reference, Cohort Platform Samples Lipids analysed
Ceramides as prognostic markers
Sigruener et al. [50], LURIC study Shotgun MS 3316 (768 incident CVD; 484 
mortality)
38 PCs, 15 LPCs, 30 PC Os, 31 PEs, 
24 PE Os, 33 SMs, 7 Cers
Cheng et al. [51], ATHEROREMO-
IVUS
LC–MS 581 (underwent angiography) 8 lipids (CEs and Cers) identified in 
LURIC study
Laaksonen et al. [52], Corogene, 
SPUM-ACS, BECAC 
LC–MS 3377 (mostly CVD patients) 4 Cers (C16:0, C18:0, C24:0, C24:1)
Havulinna et al. [54], FIN-
RISK2002
LC–MS 8101 healthy subjects (813 incident 
MACE)
4 Cers (C16:0, C18:0, C24:0, C24:1)
Wang et al. [53], PREDIMED LC–MS 1017 (230 incident cases; 787 
random samples)
4 Cers (C16:0, C22:0, C24:0, C24:1)
Anroedh et al. [46], ATHER-
OREMO-IVUS
Shotgun MS 581 (underwent angiography) 10 lipids (CEs and Cers) identified in 
LURIC study
Alshehry et al. [55], ADVANCE Targeted LC–MS 3779 (case–control) Lipidome-wide (310 lipid species)
Paynter et al. [56], WHI, PRED-
IMED
LC–MS 944 (472 incident CHD; 472 con-
trols); 627 (312 incident CHD; 
315 controls)
Lipidome-wide (217 lipids)
Poss et al. [57], Utah population LC–MS/MS 674 (462 CAD patients; 212 
controls)
32 Sphingolipids
Opposite effects of MUFA and PUFA containing phospholipids
Sigruener et al. [50], LURIC study Shotgun MS 3316 (768 incident CVD; 484 
mortality)
38 PCs, 15 LPCs, 30 PC Os, 31 PEs, 
24 PE Os, 33 SMs, 7 Cers
Alshehry et al. [55], ADVANCE Targeted LC–MS 3779 (case–control) Lipidome-wide (310 lipid species)
Wang et al. [69], PREDIMED LC–MS 1017 (230 incident CVD; 787 
random samples)
Lipidome-wide (200 lipids)
Wurtz et al. [36], FINRISK, 
SABRE, BWHHS
Targeted NMR metabolomics 7256 (800 CVD events); 2622 (573 
CVD events); 3563 (368 CVD 
events)
14 lipoprotein subclasses and fatty 
acid composition
Razquin et al. [68], PREDIMED LC–MS 983 (case–control) Lipidome-wide (202 lipids)
Mundra et al. [66], LIPID, 
ADVANCE
LC–MS 5991; 3779 Lipidome-wide (342 lipids)
TG species and risk of CVDs
Fernandez et al. [47], MDC study Shotgun MS 427 (211 incident CVD; 216 
controls)
85 lipids (TGs, DGs, CEs, SMs, PC 
Os, LPCs, PEs, PE Os)
Stegemann et al. [65], Bruneck 
study
Shotgun MS 685 (90 incident CVD) 135 lipids (PCs, LPCs, CEs, SMs, 
PSs, PEs, LPEs, TGs)
Alshehry et al. [55], ADVANCE Targeted LC–MS 3779 (case–control) Lipidome-wide (310 lipid species)
Razquin et al. [68], PREDIMED LC–MS 983 (case–control) Lipidome-wide (202 lipids)
Wang et al. [69], PREDIMED LC–MS 1017 (230 incident CVD; 787 
random samples)
Lipidome-wide (200 lipids)
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ATHEROREMO-IVUS study [51]. This led to a growing 
interest in these ceramide species among the researchers and 
several studies focusing on them added to the supporting evi-
dences of their relationship with secondary CVD outcomes 
[46, 52, 53] and future CVD events in healthy individuals 
[54]. The findings were also corroborated by lipidome-wide 
studies [55–58] and a large meta-analysis of seven cohort 
studies with over 29,800 individuals [59]. On the contrary, 
a recent study by Seah et al. that explored association of 79 
sphingolipid species with CVDs in a Chinese ethnic popu-
lation did not support the role of ceramides in CVD [60]. 
Although reasons such as difference in quantification meth-
ods and statistical power could not be ruled out, this study 
may point to the population-specific effect of lipid species on 
CVD risk. The meta-analysis by Mantovani et al. also sug-
gested that associations may be stronger for ceramides with 
long acyl chain and for those with unsaturated acyl chain 
[59]. On the similar lines, Lemaitre earlier showed associa-
tions of higher plasma levels of shorter sphingolipids (C16 
acyl chain) with increased risk of heart failure, whereas 
higher levels of longer sphingolipids (C20-24 acyl chains) 
with decreased risk of heart failure [61].
Clinical utility of prediction scores based on ceramide 
species has been proposed by several independent stud-
ies (Table 2). Laaksonen et al. [52] showed that CERT 
score based on Cer(d18:1/16:0), Cer(d18:1/18:0) and 
Cer(d18:1/24:1) and their ratios with Cer(d18:1/24:0) pre-
dict cardiovascular death in patients with stable CAD and 
acute coronary syndromes beyond LDL-C. It was further 
shown that the prognostic value of CERT score could be 
improved by adding phosphatidylcholine (PC) species [62]. 
Subsequently, the predictive value of ceramide-based scores 
have been repeatedly confirmed by many independent stud-
ies including the Framingham Heart study [63], Mayo clinic 
study [64] and FINRISK2002 [54]. All these strong evi-
dences provided basis for the ceramide-based clinical test 
recommended by the Mayo clinic [https ://news.mayoc linic 
labs.com/ceram ides-mihea rt/] to assess risk of adverse clini-
cal outcomes in CAD patients. A recent study showed that in 
addition to ceramides, sphingomyelin species (SM) could be 
important predictor of CVD and proposed a new risk score 
termed as the sphingolipid-inclusive CAD (SIC) risk score 
which included dihydro-Cer(d18:0/18:0), Cer(d18:1/18:0), 
Cer(d18:1/22:0), Cer(d18:1/24:0), SM(d18:0/24:1), 
SM(d18:1/24:0), SM(d18:1/18:0) and sphingosine [57]. 
Authors showed that the SIC risk score provides strong 
prediction value and outperform other measures including 
LDL-C and CERT score. Thus, through lipidomics-based 
studies, plasma ceramides have emerged as promising new 
diagnostic or prognostic marker for CVD with clinical 
application.
Opposite effects of MUFA and PUFA containing 
phospholipids
Many distinct phospholipid species have been consist-
ently identified as risk factor for CVDs in lipidomics-based 
studies (Supplementary Table 1) [47, 50, 55, 56, 65–69]. 
Recently, alterations in phospholipids levels in patients 
with ischemic cardiomyopathy have been shown suggesting 
the changes in metabolic profiles during progression from 
ischemic heart disease to ischemic cardiomyopathy [70]. 
Addition of phospholipids to the base model of traditional 
risk factors also improved CVD risk prediction (Table 2). 
Bruneck study showed that addition of a phosphatidyletha-
nolamine species PE 36:5 and two other lipid species to a 
model including conventional risk factors increased predic-
tion value [65]. Similarly, LIPID study [66] and ADVANCE 
trial [55] showed that addition of phospholipid species to 
the traditional risk factors improved prediction of CVD 
events and mortality (Table 2). Although clinical utility of 
lysophospholipids has also been suggested by Ganna et al. 
Table 2  Lipidome-based prediction scores for CVD risk and death
C-statistic is a standard measure of the predictive accuracy of a model)
SIC sphingolipid-inclusive CAD risk score, CER Ceramide, DG diacylglyceride, GM monosialated ganglioside, LPC lysophosphatidylcholine, 
LPI lysophosphatidylinositol, PC phosphatidylcholine, PCO phosphatidylcholine-ether, PE phosphatidylethanolamine, PEO phosphatidylethan-
olamine-ether, SM sphingomyelin
Prediction score/Study Components C-statistics
CERT1, Laaksonen et al. [52] Cer(d18:1/16:0), Cer (d18:1/18:0), Cer (d18:1/24:1), Cer (d18:1/16:0)/Cer(d18:1/24:0), 
Cer (d18:1/18:0)/Cer(d18:1/24:0), Cer (d18:1/24:1)/Cer(d18:1/24:0)
0.80 for CVD death
CERT2, Hilvo et al. [62] Cer(d18:1/24:1)/Cer(d18:1/24:0), Cer(d18:1/16:0)/PC 16:0/22:5, Cer(d18:1/16:0)/PC 
14:0/22:6, PC 16:0/16:0
0.76 for CVD death
SIC, Poss et al. [57] Cer(d18:1/18:0), Cer(d18:1/24:0), SM(d18:1/24:0), SM(d18:0/24:1)/SM(d18:1/18:0), 
Cer(d18:1/18:0)/Cer(d18:1/22:0), Sphingosine
0.79 for risk of CAD
Mundra et al. [66] PC O-34:2, PC 38:5, PI 38:3, PC O-36:1, GM3(d18:1/16:0), LPI 18:2, PE 38:6 0.65 for CVD events
Alshehry et al. [55] PC O-36:1, CE 18:0, PE O-36:4, PC 28:0, LPC 20:0, PC 35:4, LPC 18:2 0.70 for CVD events
Alshehry et al. [55] PC O 36:1, DG 16:0_22:5, SM 34:1, PC O-36:5 0.76 for CVD death
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[67], there have been inconsistent reports on the direction of 
their effect on CVDs [47, 55, 65].
An interesting observation that emerged from these stud-
ies is that the phospholipids have opposite effects on CVD 
risk based on the degree of unsaturation of their acyl chains. 
It was first observed in the LURIC study that phospholip-
ids with saturated and monounsaturated fatty acyl chains 
were positively associated with risk of CVD, while polyun-
saturated phospholipids were inversely associated with the 
CVD risk [50]. Later, several lipidome-wide investigations 
including ADVANCE trial, LIPID study, PREDIMED trial, 
WHI study and Bruneck study provided consistent findings 
(Table 1). On the similar lines, Wurtz et al. showed that 
MUFAs levels increase cardiovascular risk, while higher 
omega-6 and omega-3 PUFAs lower the risk [36]. Consist-
ently, network-based analysis of lipidome data in PRED-
IMED study also showed that the lipid species are clustered 
based on degree of unsaturation and that the cluster contain-
ing phospholipids with more double bonds was associated 
with decreased risk of CVD [69]. Thus, the lipidomics-
based studies have suggested that there are two subgroups 
of phospholipids based on the degree of unsaturation that 
have opposite effects on CVD pathophysiology.
Distinct role of TG species in CVDs
The routine clinical risk assessment quantifies the total mass 
of triglycerides, however, their contribution to the develop-
ment of CVD has been debatable as clinical trials of lower-
ing TG with fibrates provided inconsistent results [71, 72], 
whereas genetic evidence supported the causal role [73]. 
The apparent inconsistency is not surprising due to the large 
number of functionally diverse TG species in circulation that 
have varied effects (opposite directions or different mag-
nitude) on CVD risk, as revealed by high-resolution lipi-
domics. The MDC study first identified association of five 
TG species including TG 48:1, TG 48:2, TG 48:3, TG 50:3 
and TG 50:4 with adverse CVD outcome, after adjusting 
for Framingham risk factors [47]. Later, many TG species 
were found to be associated with CVD risk over a 10-year 
observation period in the Bruneck study [65], but asso-
ciations were more pronounced for TGs of lower carbon 
number and double-bond content (saturated and MUFAs). 
Similarly, ADVANCE study found inverse association of 
TG 56:6 with recurrent CVD incidence and CVD mortality 
[55] whereas PREDIMED trial showed that short TGs were 
associated with increased risk of CVD [68]. These findings 
were further supported by the network and cluster analysis 
of lipidome in PREDIMED trial which showed that satu-
rated TGs cluster consisting mainly of DGs and TGs with 
saturated fatty acids was associated with increased CVD 
risk [69]. These studies clearly suggest that abnormalities 
in different TG molecular species levels could have different 
pathological consequences, which might not be detected in 
enzymatic measurement of total triglycerides, as evident 
from a study that found decrease in a TG species without 
observed change in total triglycerides [74].
Genetic regulation of lipidome
Despite the expected influence of dietary intake on the circu-
latory lipids, contribution of genetic factors in endogenous 
regulation of lipid metabolism is well recognized. Studies 
using pedigree information and genetic data have shown 
that 10−60% of the variation in plasma levels of circula-
tory lipid species is contributed by the genetic factors, with 
considerable variation across lipid categories [12, 75–77]. 
For example, in general, sphingolipids have higher herit-
ability than glycerophospholipids, with ceramides having 
highest estimated SNP-based heritability (35–40%) and 
phosphatidylinositols with the least heritability (11–31%) 
[12]. Interestingly, genetic mechanisms do not regulate all 
human plasma lipid species belonging to a lipid class in the 
same way [12, 75, 76], as also observed in mice lipidomics 
studies [78, 79]. Rather, it seems to depend on the length 
and degree of unsaturation of the acyl chains. For instance, 
lipids containing polyunsaturated fatty acids have higher 
heritability compared to other lipid species [12]. It is also 
reported that phosphatidylcholine species (PCs) with larger 
number of carbon atoms have lower heritability estimates, 
while PCs with a larger number of double bonds have higher 
heritability [80].
Although over 400 genomic loci are now known to 
influence the plasma traditional lipid levels [81, 82], their 
effects on detailed lipid metabolism at molecular levels are 
not completely known. As epidemiological studies have 
demonstrated that distinct molecular species (e.g., TGs and 
PCs) have different or opposite effect on disease outcomes, 
genetic variants/loci could potentially have different effect 
on functionally diverse lipid species. To ascertain that, sev-
eral genome-wide association studies have been performed 
with individual lipid species (Table 3) [12, 38–45, 83–100]. 
These studies have not only identified several new loci/
genes contributing to lipid metabolism, but also provided 
novel mechanistic insights to the known loci identified for 
traditional lipids. The major findings of these GWASs are 
discussed here. Figure 4 illustrates the genes identified for 
different lipid categories and their overlap. The list of all the 
genetic variants reported to be associated in these studies is 
provided in Supplementary Table 3.
Sphingolipids
The first genetic investigation of sphingolipids was per-
formed by Geiger et  al. in 2008 [83], that included 85 
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sphingolipids and 284 individuals of the KORA study. 
The study identified two loci for sphingolipids-PLEK and 
ANKRD30A at genome-wide significance that did not stand 
multiple testing correction. Later, large-scale studies for 33 
sphingolipids including over 4400 subjects from 5 diverse 
European populations identified 7 loci- ATP10D, FADS1-
2-3, SGPP1, CERS4, SPTLC3, APOE and GLTPD2-PLD2 
[84, 87]. As most of the loci identified by Hicks et al. [84] 
contains genes encoding enzymes involved in sphingolipids/
ceramide synthesis (Fig. 3), and none of the genes involved 
in ceramide degradation or signaling was identified, authors 
speculated that the plasma levels of ceramide are primarily 
regulated by genes involved in ceramide production. Given 
the prominent roles of these genes in sphingolipid metabolic 
pathways, association of these genes were subsequently 
replicated in many studies [12, 85, 92, 95]. Furthermore, 
new loci were also discovered by studies with larger sam-
ple sizes including PDE4D and CERS6 [88, 100]. A recent 
metabolomics-based GWAS in 7 European cohorts with total 
sample size of over 7,000 that included 14 sphingomyelins 
confirmed previous associations of SPTLC3, APOE, SGPP1, 
CERS4 with sphingomyelins, but no new locus was identi-
fied [13].
From these studies, 6 genes (SPTLC3, CERS4, CERS6, 
SGPP1, GLTPD2 and FADS1-2-3) with direct role in cera-
mide metabolism have emerged as prominent regulator of 
plasma levels of ceramides. The rate of ceramide synthesis 
is regulated by the first step of de novo pathway, which is 
catalyzed by serine palmitoyltransferase (SPT). SPTLC3 
codes for a subunit of the SPT complex which catalyses the 
condensation of serine with palmitoyl-CoA (Fig. 3). The 
increased expression or activity of SPTLC3 could result in 
increased ceramide production by increasing the influx of 
sphinganine in de novo pathway (Fig. 3). Several cis-eQTLs 
(expression quantitative trait) of SPTLC3 (GTEx v7) are 
found to be associated with plasma levels of ceramides and 
sphingomyelins (Supplementary Table 3), suggesting that 
genetic effect of SPTLC3 variants is mediated by regulat-
ing the expression of the gene. SPT product sphinganine 
is then metabolized to dihydroceramides by the addition of 
different acyl-chains by ceramide synthases (CerS) [101], 
which is subsequently converted to ceramides and sphingo-
myelins. CerS also catalyzes the conversion of sphingosine 
to ceramide in the salvage pathway. Six isoforms of CerS 
(CerS1-6) exist in humans with different preferences for 
specific fatty acids. CerS4 has high selectivity towards long 
acyl chains (C18-C20) while CerS6 has preference for short 
acyl chains (C14-C16) [102]. Consistently, association of 
variants in CERS4 that encode CerS4, with ceramides and 
SMs containing C18-C20 acyl chains have been identified 
repeatedly in many studies (SupplementaryTable 3).
FADS1-2-3 locus encodes three enzymes that regulate 
desaturation of fatty acids and production of unsaturated 
fatty acids. Unsaturated ceramides are synthesized by the 
incorporation of unsaturated fatty acids into sphingosine/
sphinganine bases. Association of variants in the FADS1-2-
3 locus with unsaturated ceramides levels suggests crucial 
role of fatty acid desaturases in generation of unsaturated 
ceramides and sphingolipid metabolic pathways [84]. On 
the other hand, SGPP1 codes for sphingosine-1-phosphate 
phosphohydrolase 1 that play important role in salvage path-
way. SGPP1 belongs to the phosphatase super-family that 
converts sphingosine-1-phosphate to sphingosine that is 
readily metabolized to ceramide. Enhanced SGPP1 activity 
could lead to elevated sphingolipid levels by shifting the 
stochiometric balance towards sphingosine and ceramide 
Fig. 4  Genetic loci identified in 
GWAS with lipidome. Genetic 
loci identified for different 
lipid classes and their overlap 
are shown. Genes highlighted 
in red font have direct role in 
lipid metabolic pathways. SMs: 
Sphingomyelins; PLs: Phospho-
lipids; CEs: Cholesteryl esters; 
TGs: Triacylglycerides
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production. Consistently, variants in SGPP1 have shown 
association with circulating sphingomyelins, mainly con-
taining C14-C16 and C22-C24 acyl chains. GLTPD2 codes 
for glycolipid transfer protein domain-containing protein 2 
and has putative role in transfer of ceramide-1-phosphate. 
Thus, findings from the major GWASs on sphingolipids sug-
gest that the plasma levels of ceramides and sphingomyelins 
are primarily driven by the genes involved in sphingolipid 
metabolism, particularly ceramide biosynthesis (Fig. 3).
Glycerolipids
Only a few GWASs have included molecular TG species 
[12, 13, 88, 94]. The study by Rhee et al. in over 2,000 par-
ticipants from Framingham Heart Study (FHS) included 46 
TG species and revealed association of FADS1-2-3, GCKR 
and APOA1-5 loci with several TG species [88]. These genes 
with direct role in triglyceride metabolism were subse-
quently replicated in other GWASs [12, 94]. The lead GCKR 
variant rs1260326, a missense variant (L446P) associated 
with TG species, is established as the likely causal vari-
ant through functional studies [103, 104]. In another study 
by Rhee et al. that focused only on the rare variants, no 
additional variants for TGs could be identified [94]. How-
ever, recent studies have suggested association of common 
variants at new loci for TGs. Our previous study suggested 
new signals for TGs at genetic variants in or near KAZN, 
VWA3B, ABLIM2, PDHA2, PTPRN2, LPL, APOA5, CD33 
and MIR100HG at genome-wide significance that did not 
remain significant after multiple testing correction [12]. 
Also, Demirkan et al. identified association between a new 
locus MLXIPL and TGs (TG 48:1 and TG 50:1) [13].
Interestingly, similar to epidemiological finding that dif-
ferent TG species have different effect on CVD risk, find-
ings from the genetic studies revealed different patterns 
of association of TG species with genetic variants. GCKR 
demonstrated a stronger association with TGs of relatively 
lower carbon content (TG 48:2, TG 48:3, TG 50:3, TG 50:2, 
TG 50:4) [13, 88], while APOA1/A5 and LPL have stronger 
effect on medium length TG species (TG 54:4, TG 52:3, 
TG 52:4) [12, 88]. On the other hand, FADS1-2-3 asso-
ciate with TGs in a fatty acid saturation specific manner, 
with the direction of effect differed at the extremes of TG 
carbon content, and strongest association with TGs of rela-
tively higher carbon and double bond content such as TG 
58:10 and TG 58:11 [13, 88]. Such a pattern of association 
was also observed in one of the loci identified in GWASs 
for enzymatically measured triglycerides-CILP2 that had 
different effect sizes across different TG species and was 
mainly associated with the unsaturated TGs [13]. These 
findings suggest that genes involved in TG metabolism have 
species-specific effect that apparently depend on the length 
of acyl chains. Further light on this was provided by our 
previous study which showed that a genetic variant at LPL 
locus (rs11570891) increases the expression and enzymatic 
activity of LPL [12]. We further showed that the increased 
LPL enzymatic activity had stronger effect on medium 
length TGs than other TGs. Taken together, GWAS findings 
suggest that genetic regulation of TGs is determined by their 
carbon content and degree of unsaturation and further rein-
force that such effects might not be detected by enzymatic 
measurement of total triglycerides.
Phospholipids
A number of genetic loci have been associated with plasma 
levels of distinct phospholipids species, including genes with 
direct role in phospholipid metabolism (Table 3; Fig. 4). In 
the KORA study that included 208 phospholipid species, 
Geiger et al. [83] identified association of phospholipids with 
FADS1-2-3 and LIPC. Later, Illig et al. [85] identified five 
loci for phospholipids-FADS1-2-3, ELOVL2, PLEKHH1, 
SYNE2 and SPTLC3 in a larger dataset. Further, a compre-
hensive genetic investigation of phospholipids with 57 PCs, 
20 lyso PCs, 27 PEs, 15 plasmalogens in over 4000 samples 
identified 25 loci at genome-wide significance [87]. In the 
pathway analysis, 13 genes (KCNH7, AGPAT1, PNLIPRP2, 
SYT9, FADS2, DAGLA, DLG2, APOA1, APOC3, ELOVL2, 
CDK17, LIPC and PLA2G10) located in 11 loci from the 25 
loci were mapped to the glycerophospholipid metabolism 
pathway [87]. Several additional loci for phospholipids were 
discovered as illustrated in Fig. 4 and listed in Supplemen-
tary Table 3. Here we discuss two examples that highlight 
the potential of lipidomics in identifying new lipid modify-
ing genes and providing mechanistic insights to the known 
lipid loci.
MBOAT7 encodes a lysophosphatidylinositol acyl-
transferase that incorporates arachidonic acid (C20:4) 
into lysophosphatidylinositol (LPI) to generate phosphati-
dylinositols (PI) [105]. The activity of MBOAT7 regulates 
the levels of free arachidonic acid and its availability for 
eicosanoid production which mediates pro-inflammatory 
signalling [106]. Consistent with its biochemical function, 
Shin et al. identified association of variants in MBOAT7 
with the ratio of arachidonate (20:4n6) to 1-arachidonoyl-
glycerophophoinositol [90]. Later, its association with PI 
species was confirmed in other studies [12, 96]. MBOAT7 
variants also increase the susceptibility to liver disorders 
including liver cirrhosis and non-alcoholic fatty liver dis-
ease (NAFLD) by inducing a reduction in its expression in 
liver [107–109]. Notably, our previous study also suggested 
association of MBOAT7 variant with venous thromboem-
bolism [12]. The example of MBOAT7 further exemplifies 
that lipidome-based GWAS could identify new genes with 
prominent role in lipid metabolism that could not be detected 
through GWAS of traditional lipids.
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Fatty acid desaturase (FADS) gene cluster has been consist-
ently reported to be associated with omega-3 and omega-6 
fatty acids levels with inverse effects on different PUFAs [43, 
44, 83, 87]. The FADS gene cluster contains genes coding 
for three key enzymes in PUFA metabolism-FADS1 (delta-5 
desaturase), FADS2 (delta-6 desaturase) and FADS3 (delta-9 
desaturase). The delta-6 desaturation by FADS2 generates 
gamma-linolenic acid (C18:3 n-6) and stearidonic acid (C18:4 
n-3) from linoleic acid (C18:2 n-6) and alpha-linolenic acid 
(C18:3 n-3) respectively, that by elongation yield dihomo-
gamma-linolenic acid (C20:3 n-6) and eicosatetraenoic acid 
(C20:4 n-3) [110]. Further, delta-5 desaturation of dihomo-
gamma-linolenic acid by FADS1 generates arachidonic acid 
(C20:4 n-6) and eicosapentaenoic acid (C20:5 n-3). Genetic 
variants in FADS1 and FADS2 genes are associated with the 
increased levels of phospholipids with three or less double 
bonds while with the decreased levels of phospholipids with 
four or more double bonds [12, 83]. We previously showed 
that a variant in FADS2 increases FADS2 expression while 
reduces the expression of FADS1 that explain the inverse rela-
tionship of FADS2 variants with lipids containing different 
polyunsatureated fatty acids (PUFAs) [12]. The association of 
FADS1-2-3 locus with the reduced levels of lipids containing 
arachidonic acid may also explain its assocition with reduced 
risk of atherosclerotic CVD outcomes-peripheral artery dis-
esae (PAD) and aterial embolism and thrombosis [12]. The 
example of FADS1-2-3 along with other known lipid genes 
such as LPL, GCKR (discussed above) highlights how detailed 
lipidomic profile could provide the mechanistic understanding 
of effects of well-established lipid loci.
Sterols
Sterol lipids including CEs are not represented well in the 
GWASs with lipidome or metabolome, and only two studies 
have reported association of CEs with genetic variants [12, 
88]. Rhee et al. [88] identified four loci associated with CE 
species- FADS1-2-3, GNAL, NTAN1 and SEC61G. We found 
previously association of three loci with CEs-ABCG5/8, 
FADS2 and SYNGR1. ABCG5/G8 codes for ABC cholesterol 
transporters G5 and G8, that have been associated with total 
cholesterol, LDL-C and cholesterol esters in LDL. However, 
our study revealed a novel association of ABCG5/G8 variant 
with a specific CE species- CE 20:2;0. All of the identified 
loci for CEs overlap with the loci associated with phospho-
lipids (Fig. 4).
Discussion
It is apparent from epidemiological and genetic studies that 
lipidomics has great potential in revealing new biology not 
captured by traditional lipids and lipoprotein measurements. 
Lipid species measurements, like other intermediate pheno-
types, increases statistical power to detect genetic associa-
tions and hence provide opportunity to discover new lipid 
loci [12, 111]. In an analysis with over 500 known genetic 
variants for traditional lipids, we previously showed that as 
compared to traditional lipids, associations with detailed 
molecular lipids are several orders of magnitudes stronger 
for the variants in or near genes involved in lipid metabolism 
such as FADS1-2-3, LIPC, ABCG5/8, SGPP1, SPTLC3 [12]. 
This demonstrates the prospects of lipidomics in identifying 
lipid-modulating variants, particularly the ones with direct 
role in lipid metabolism. Consistently, GWASs with distinct 
lipid species discovered many new genes with direct role in 
lipid metabolic pathways and provided new insights into the 
genomic loci associated with traditional lipids. For instance, 
detailed TG profiles revealed that the total triglycerides asso-
ciated loci such as GCKR, FADS1-2-3, LPL, APOA5 drive 
association of distinct TG species depending on number 
of carbon atoms and degree of unsaturation, as discussed 
above.
Integrating lipidomics and genomics: opportunities 
beyond GWAS
After the success of the GWASs in identifying new genomic 
loci associated with lipid species, one of the next challenges 
is to translate these findings towards predictive and personal-
ized medicine. Emerging tools in genomics provides many 
new opportunities in this direction [112]. This is demon-
strated by the success of genetic studies guiding the develop-
ment of antibodies targeting PCSK9 (proprotein convertase 
subtilisin/kexin type 9) to treat hyperlipidemia and CVD 
[113]. Here we discuss approaches that could be used to 
translate the statistical associations identified in epidemio-
logical studies and GWASs to biological understanding, 
drug target identification and disease risk characterization 
(Fig. 5).
Inferring causality towards drug targets 
development
Epidemiological studies have provided strong evidence of 
association of several distinct lipid species with CVD out-
comes. However, it cannot be inferred from simple obser-
vational studies which of these associated lipid species have 
causal effect on CVDs. Nonetheless, genomics provides an 
alternative approach to infer causality using the intrinsic 
properties of the genome, i.e., the random assortment of 
alleles at conception, in a statistical framework referred as 
Mendelian randomization (MR) [114–116]. MR is a rou-
tinely used genetic tool in observational studies which uses 
genetic variants as proxies for exposure variable (risk fac-
tors) to infer whether the increased or decreased risk factor 
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causes the disease [41, 117, 118]. First described in 1986 
[119], many methods and approaches in MR analysis have 
been developed that allow use of GWAS summary statistic 
data for risk factor and disease of interest, either from one 
dataset (one-sample MR) or two datasets (two-sample MR) 
[114]. Development of two-sample MR methods using the 
existing and publicly available GWAS summary data has 
made MR analysis increasingly easy and popular.
With the improved understanding of the genetic archi-
tecture of lipidome and availability of large-scale GWAS 
summary statistics data both for lipidome and CVD, MR 
provides an excellent avenue to infer the causal role of the 
CVD associated lipid species. Efforts at this front have been 
limited so far, most likely due to the highly correlated nature 
of the high-dimensional lipidome profiles. Ganna et al. [67] 
used summary stats from CARDIoGRAMplusC4D to reveal 
causal effect of MG 18:2 on CHD risk. On the other hand, 
a recent study performed a MR analysis to investigate the 
causal relationship between PC 38:3 and P wave duration 
(PWD, an indicator of atrial conduction) [120]. The study 
found that PC 38:3 and PWD association is not causal and is 
mediated by BMI. Larger efforts are required to highlight the 
lipid species with therapeutic potential from the large num-
ber of associations for follow-up investigations, as exhibited 
in a recent MR analysis [121]. The study performed GWAS 
on untargeted plasma metabolome with  ~ 11,000 metabo-
lites in  ~ 10,000 individuals and used two-sample MR 
approach to assess the causal effect of both identified and 
unidentified metabolites on 45 common diseases. The study 
provided evidence of causal effect of 31 metabolites on at 
least one of the 5 diseases- CHD, schizophrenia, bipolar dis-
order, rheumatoid arthritis, primary sclerosing cholangitis. 
Among the causal metabolites, 19 metabolites were causal 
for coronary heart disease and 6 of which were found to be 
associated with incident CHD. Recent development of multi-
variate MR methods provides a powerful tool to incorporate 
high-dimensional data like lipidome profiles in MR analysis 
[122–124]. Application of these approaches to infer the cau-
sality of CVD associated lipid species is one of the ways to 
move forward in the direction of drug target development.
Refining GWAS signals to causal variants to reveal 
metabolic networks
Although GWASs have been successful in identifying new 
genomic loci associated with lipid species, the associated 
variant, in most cases, does not cause the trait or disease 
itself but serve as surrogate for neighbouring SNPs in a 
large genomic region that are in linkage disequilibrium 
(LD) with it. Because of the complex LD patterns among 
the SNPs, pinpointing causal variants from the associ-
ated variants is a challenging task. However, statistical 
fine-mapping approaches allow the refinement of the trait-
associated regions to identify genetic variants with likely 
causal influence on the trait [125, 126]. The fine-mapping 
approach in lipidomics could not only help in refining the 
Fig. 5  Approaches to move 
beyond GWAS. New opportuni-
ties and prospects of application 
of genomics to translate find-
ings from lipidomics to develop 
better predictive and preventive 
strategies are illustrated
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genomic loci but the multidimensional association data 
may also help in highlighting the metabolite-specific 
effects and hence reveal new metabolic networks. For 
instance, Gallois et al. [127] performed fine-mapping of 
LIPC region which suggested that there are at least three 
distinct sites with metabolite-specific variants within the 
gene. The study showed that large HDL and triglyceride in 
lipoproteins are influenced by all the three sites in LIPC. 
But interestingly, intermediate density lipoproteins (IDLs) 
and fatty acids are mostly influenced by two sites and very 
small VLDL (very low-density lipoprotein) are influenced 
by only one of sites in the gene [127]. On the similar note, 
earlier Tukiainen et al. [111] showed that LIPC region has 
opposite associations between the lipid measures of larger 
and smaller HDL particles.
Another commonly used approach is targeted sequenc-
ing of the trait-associated region that allow identification 
of rare coding or loss-of-function (LoF) variants with puta-
tive causal effects in the region [128–132]. Exome or whole 
genome sequencing allow the identification of full spectrum 
of variants, including rare and loss-of-function variants that 
may have direct functional effects than the common variants 
[99, 133, 134]. Due to the limited sample sizes, the sequenc-
ing efforts have been so far less successful in lipidomics and 
only a few rare or LoF variants influencing lipid levels could 
be discovered [96–99]. Long et al. identified seven rare 
variants in four genes (ACADS, CRAT , DMGDH, ETFDH) 
involved in fatty acid metabolism [96]. Thus, larger sequenc-
ing efforts are required to better understand the potential 
role of rare coding variants involved in lipidomic variation.
Further insight to the putative causal variant could also be 
provided by integrating GWAS results with other “omics” 
data such as transcriptome, proteome and epigenome. About 
80% of the genetic variants identified by the GWASs lie in 
the non-coding regions, thus exploring the association with 
gene expression levels (eQTLs), protein levels (pQTLs) and 
epigenetic changes such as DNA methylation in relevant tis-
sues could provide information about the biological effects 
of the variants and putative causal genes. Also, utilizing the 
phenome-wide association (PheWAS) data for thousands 
of clinical outcomes from biobanks such as UK Biobank 
(https ://www.ukbio bank.ac.uk/) and FinnGen (https ://www.
finng en.fi/en) could further provide mechanistic insights. To 
facilitate the efforts in this direction, colocalization tools 
have been developed in recent years that can integrate multi-
omics datasets such as GWAS, eQTLs, pQTLs and PheWAS 
data using statistical methods [135–137]. The colocalization 
analysis by Franceschini et al. provided evidence for the role 
of novel genes in the subclinical measures such as carotid 
intima-media thickness (cIMT) and carotid plaque formation 
and provided insights into the regulatory mechanisms link-
ing atherosclerosis and clinical outcomes [137].
Predicting CVD risk using lipidome‑based genetic 
risk scores
Early prediction and prevention could greatly reduce the 
enormous socio-economic burden of the CVDs [138]. The 
intensity of risk management regime is generally guided by 
the risk estimates of the individuals [139], which are not 
always precise [140]. Moreover, existing clinical risk assess-
ment tools, that typically include traditional plasma lipids, 
identify individuals with high CVD risk at a stage when ath-
erosclerotic events have already developed. Polygenic risk 
scores (PRS), a weighted sum of the number of risk alleles 
carried by an individual, has shown potential in early predic-
tion, but currently have limited clinical utility [141–144]. 
Thus, the quest for better and early-stage prediction scores 
to maximize the benefits of risk management has been the 
focus of the CVD research, but have provided limited suc-
cess so far [145, 146].
One of the challenges in early CVD detection and preven-
tion is the heterogeneity owing to the diverse pathological 
conditions that are preceded by atherosclerotic and meta-
bolic events developing at young age [147], resulting in dif-
ferent CVD subtypes. Hence, individuals’ predisposition 
to different subtypes is influenced by multiple independent 
risk factors that need to be understood and incorporated in 
prediction algorithms to guide appropriate and personal-
ized interventions. Traditional lipid profiling that measures 
HDL-C, LDL-C, triglycerides and total cholesterol, does 
not reflect precise molecular perturbations in lipid metabo-
lism underlying CVD subtypes. Moreover, a PRS based on 
genetic loci for CVD represents a combination of genetic 
risk factors acting through different pathways, whose roles 
may vary in different CVD subtypes. In such scenario, indi-
viduals would respond very differently to the same risk 
management strategies. As revealed by genetic studies of 
lipidome that many genomic loci have lipid species specific 
effects, integrating information of genetic variants of lipid-
omic measures in PRS algorithms could provide more spe-
cific and sensitive CVD risk stratification than those based 
on CVD variants. Our proposition is that the risk prediction 
model should incorporate information on perturbations in 
individual’s lipidome profile and their genetic determinants. 
Thus, the next challenge is to develop predictive tools to 
incorporate the genetic data on high-dimensional lipidome 
profiles.
Conclusion
The increasing global burden of CVDs highlights the press-
ing need for better personalized prediction and prevention 
strategies. One key step is to open new therapeutic opportu-
nities by understanding the causal roles of lipid metabolism 
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at molecular lipid species/sub-species resolution in heter-
ogenous CVDs etiologies and their regulation by genetic 
and lifestyle factors. To this end, the technological advances 
in lipidomics and other omics technologies have led to a 
tremendous progress in the CVD research field in last two 
decades. Lipidomics has not only provided a closer look at 
the lipid metabolic perturbations in CVDs, but has improved 
our understanding of the genetic control of lipid metabo-
lism. Further improvement in technologies will continue to 
improve our understanding of CVDs. However, the ultimate 
goal of a personalized translational research is to find the 
right intervention (target biomarker) for right individual 
(CVD subtype) at the right time (at early stage). Integrat-
ing the emerging genomics tools with the high-dimensional 
lipidome holds a great potential in moving towards this goal. 
We discussed some of the commonly used approaches in 
translational research that could be employed in lipidomics-
based studies, however further advancements in statistical 
and computational tools would be required to deal with the 
high-dimensional and correlated structure of the lipidome 
profiles.
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